Seres Therapeutics, Inc. (MCRB)
Chart Events
Performance Outlook
| Previous Close | 26.71 |
| Open | 26.45 |
| Bid | 24.48 x 1100 |
| Ask | 24.60 x 1100 |
| Day's Range | 24.37 - 26.69 |
| 52 Week Range | 2.52 - 38.50 |
| Volume | 1,265,058 |
| Avg. Volume | 963,587 |
| Market Cap | 2.234B |
| Beta (5Y Monthly) | 4.05 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.20 |
| Earnings Date | Nov 09, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 37.50 |
- Barrons.com
Want to Use ETFs to Play Biotech? Choose Wisely.
Differences in focus, size of holdings, and weightings add to difficulty in choosing the right fund. Why ARK Genomic Revolution and SPDR S&P Biotech ETFs stand out.
- Business Wire
Seres Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference
Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it will present a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14 at 11:40 a.m. ET.
- Business Wire
Seres Therapeutics Publishes Positive SER-287 Phase 1b Ulcerative Colitis Study Results in Journal Gastroenterology
Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced the publication of data analyses from the Company’s Phase 1b trial of SER-287 in patients with active mild-to-moderate ulcerative colitis (UC), most of whom were failing current therapies. The study results demonstrated that SER-287 administration was associated with positive impacts on clinical remission, endoscopic improvement, modulation of the gastrointestinal microbiome, and a favorable tolerability profile.
